"Fakultná nemocnica Trnava je najväčším poskytovateľom zdravotnej starostlivosti v Trnavskom kraji. Na 641 lôžkach odliečime viac ako 20 tisíc pacientov ročne. Náš kvalifikovaný personál realizuje liečebno-preventívny a ošetrovateľský proces s cieľom zaistiť maximálnu spokojnosť našich pacientov."

During the past decade, Fakultná Nemocnica Trnava conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 6 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fakultná Nemocnica Trnava" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Arcus Biosciences, Inc." with 1 trials sponsored, "Bayer" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fakultná Nemocnica Trnava" #1 collaborator was "Epidemiological and Clinical Research Information Network" with 2 trials as a collaborator, "Aarhus University Hospital" with 1 trials as a collaborator, "CHU de Reims" with 1 trials as a collaborator, "Charles University, Czech Republic" with 1 trials as a collaborator and "Eppdata GmbH Hamburg, Germany" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Fakultná Nemocnica Trnava" are "Multiple Sclerosis" (5 trials), "Acute Ischemic Stroke" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Acute Non-cardioembolic Ischemic Stroke" (1 trials) and "Anemia" (1 trials). Many other conditions were trialed in "Fakultná Nemocnica Trnava" in a lesser frequency.

Most popular intervention types in "Fakultná Nemocnica Trnava" are "Drug" (22 trials), "Biological" (2 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (3 trials), "Placebo" (3 trials), "Mavenclad®" (2 trials), "Ancrod (Viprinex)" (1 trials) and "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fakultná Nemocnica Trnava" are 24 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Fakultná Nemocnica Trnava". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Fakultná Nemocnica Trnava, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Fakultná Nemocnica Trnava, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".

Fakultná Nemocnica Trnava has several departments that took part in Clinical trials: "Kardiologicka ambulancia" - 2 trials